SPHK2 and breast cancer: Antoon et al. disclosed that ER-negative resistant breast cancer cells overexpressed SPHK; and specific inhibition of SPHK2 by ABC294640 decreased the growth of chemoresistant breast cancer cells in vivo enhancing doxorubicin and etoposide-induced apoptosis when using combined therapy (79).